• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Compared to prior infection, prior vaccination is associated with greater neutralization capacity against all COVID-19 variants

byRand Firas KhasawnehandAlex Chan
November 3, 2021
in Infectious Disease, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Vaccine boosters appear to be indicated for emergent SARS-CoV-2 variants in the future. 

2. Although both previously infected and not previously infected participants displayed neutralization capacity against all variants of COVID-19, those who had been previously infected displayed overall better neutralization capacity. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Billions of vaccine doses have been administered worldwide as an effective means to reducing the healthcare and societal burden of SARS-CoV-2. Researchers in this study sought to further characterize the difference in immune responses triggered by vaccination compared to prior SARS-CoV-2 infection, and how this may result in differences in immunity against emerging mutant variants. Participants in the study were separated by previous infection status (with those that were previously infected having been infected between April and December 2020). The participants’ neutralization status to the panel of SARS-COV-2 isolates were determined. Previously infected vaccinated individuals were found to have higher PRNT50 titers against the SARS-CoV-2 isolates than non-previously infected vaccinated individuals. The majority of isolates had a higher NAb response in previously infected vaccinated participants than non-previously infected vaccinated individuals. The results found in this study strongly suggest the benefit of vaccine boosters for SARS-COV-2 for emerging variants. Strengths of this study include the accuracy of the data gathered. The participants in this study were followed longitudinally before and after vaccination. Limitations include the sample size of the study (40 participants) and the lack of diversity of the participants (primarily young Caucasian women). Study findings suggest that both prior infection and vaccination will result in neutralization capacity against COVID-19 variants. However, the benefits of vaccination as demonstrated by the superior neutralization capacity of individuals further proport the vital role of vaccination in the pandemic. 

Click to read the study in Nature Publishing Group

Relevant Reading: mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

In-Depth [prospective cohort study]: Participants in the study were health care workers at Yale New Haven Hospital who were vaccinated between November 2020 and January 2021 and  volunteered for the study. Participants in the study were separated by previous infection status (with those that were previously infected having been infected between April and December 2020). Samples of Plasma and PBMCs were collected from participants at various intervals: prior to receiving the vaccine, 7- and 28- days after first vaccination dose, and 7-, 28- and 70 days after second vaccination dose. Data was analyzed using flow cytometry, neutralization, and ELISA assays. Previously infected vaccinated individuals were found to have higher PRNT50 titers against the SARS-COV-2 isolates than non-previously infected vaccinated individuals. The majority of isolates had a higher NAb response in previously infected vaccinated participants than non-previously infected vaccinated individuals.

RELATED REPORTS

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: COVID-19immunologySARS-CoV-2vaccination
Previous Post

Respiratory fluroquinolone treatment associated with increased short-term risk of sudden cardiac death compared to amoxicillin-based antibiotics

Next Post

Ozanimod effective for induction and maintenance therapy of ulcerative colitis

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Cardiology

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

June 30, 2022
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

June 30, 2022
#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Emergency

Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients

June 27, 2022
Next Post
Patient Basics: Ulcerative Colitis

Ozanimod effective for induction and maintenance therapy of ulcerative colitis

X-ray after foreign body removal by esophagoscopy is not cost effective

Lower dose and shorter duration of amoxicillin treatment noninferior to higher dose and longer treatment in children with community-acquired pneumonia

Screening for asymptomatic atrial fibrillation does not reduce risk of stroke despite higher detection rates

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.